<DOC>
	<DOCNO>NCT01070680</DOCNO>
	<brief_summary>In pilot prospective non-commercial clinical trial investigator study use dexmedetomidine adjuvant patient-controlled propofol sedation placebo-controlled randomized manner patient drug addiction Endoscopic Retrograde Cholangiopancreatography ( ERCP ) . Dexmedetomidine sedative medication use mostly intensive care unit , market brand name Precedex . Dexmedetomidine sedative , analgesic , sympatholytic , anxiolytic property . It produce sedation without cause significant respiratory depression . Recent research suggest dexmedetomidine effective treatment alcohol withdrawal sign . In previous study dexmedetomidine insufficient sedative agent ERCP colonoscopy , assessed sedation patient chronic pancreatitis . The main objective trial evaluate dexmedetomidine reduce propofol opioid consumption facilitate performance ERCP patient chronic pancreatitis due drug addiction.Secondary objective trial stability vital sign safety , patientsÂ´ satisfaction plus recovery time sedation . 50 elective ERCP patient chronic pancreatitis write informed consent randomisation recruit study . Exclusion criterion : allergy propofol , opioid dexmedetomidine , ASA class great 3 . All patient receive patient-controlled propofol sedation . In dexmedetomidine group dexmedetomidine infusion start sedation begin placebo group placebo-solution ( NaCl0,9 % ) administer similar manner.Standard monitoring vital sign apply , also sedation degree evaluate sedation score . At end procedure total amount propofol opioid calculate , patient endoscopists satisfaction difficulty ERCP assess .</brief_summary>
	<brief_title>Dexmedetomidine Versus Placebo Endoscopic Retrograde Cholangiopancreatography ( ERCP ) Sedation</brief_title>
	<detailed_description />
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>Elective ERCPpatients chronic alcohol pancreatitis Allergy dexmedetomidine , propofol opioid , ASA ( American Society Anaesthesiology ) class grater 3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>ERCP</keyword>
	<keyword>dexmedetomidine</keyword>
	<keyword>propofol</keyword>
	<keyword>patient-controlled sedation</keyword>
	<keyword>Chronic Alcoholic pancreatitis</keyword>
</DOC>